Full history for every metric is available with a Kvantra account
Apontis Pharma AG (APPH.DE)
Key financial summary
Financials in EUR| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 40 | 39 | 51 | 56 | 37 | 48 | 52 |
| Operating profit | €m | 1 | -0 | |||||
| Net profit | €m | -2 | -1 | -1 | 3 | -11 | 1 | 1 |
| EPS reported | € | 0.09 | 0.08 | |||||
| Operating cashflow per share | € | -0.35 | -0.35 | |||||
| Capex per share | € | 0.28 | 0.28 | |||||
| FCF per share | € | -0.63 | -0.63 | |||||
| Free cash flow | €m | -5 | -1 | |||||
| Net debt | €m | -15 | -11 | |||||
| Book value equity | €m | 31 | 32 | |||||
| Book value per share | € | 3.72 | 3.80 | |||||
| Number of shares | m | 8.33 | 8.33 | |||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 111.05 | - | |||||
| P/B LTM | x | 2.70 | 2.90 | |||||
| P/S LTM | x | 1.73 | 1.77 | |||||
| P/FCF LTM | x | -15.97 | -87.75 | |||||
| EV/EBITDA LTM | x | 19.16 | 27.54 | |||||
| EV/Sales LTM | x | 1.41 | 1.55 | |||||
| Earnings Yield LTM | % | 0.90% | 0.82% | |||||
| FCF Yield | % | -6.26% | -1.14% | |||||
| Quality | ||||||||
| ROE | % | 2.43% | 2.46% | |||||
| ROIC | % | 2.09% | 2.09% | |||||
| Operating margin | % | 2.61% | 2.61% | |||||
| Gross margin | % | 57.16% | 57.16% | |||||
| FCF/Sales | % | -10.81% | -10.81% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +31.12% | +27.42% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | -4.34 | -4.34 | |||||
| EBIT/Net interest | x | 7.44 | 7.44 | |||||
| Net debt/market cap | % | -18.46% | -12.42% | |||||
| Net debt/Equity | x | -0.50 | -0.36 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Operating within Germany, Apontis Pharma AG specializes in the marketing and distribution of pharmaceutical products, with a particular emphasis on internal medicine. The company is actively involved in the development, promotion, and commercialization of a diverse portfolio, which includes combination single-pill therapies and other medications. Key therapeutic areas of focus encompass cardiovascular diseases, such as high blood pressure (hypertension), elevated cholesterol (hyperlipidemia), and strategies for secondary prevention, in addition to respiratory ailments and diabetes. Established in 1946, Apontis Pharma AG maintains its corporate headquarters in Monheim am Rhein, Germany.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Apontis Pharma AG (APPH.DE)
Operating within Germany, Apontis Pharma AG specializes in the marketing and distribution of pharmaceutical products, with a particular emphasis on internal medicine. The company is actively involved in the development, promotion, and commercialization of a diverse portfolio, which includes combination single-pill therapies and other medications. Key therapeutic areas of focus encompass cardiovascular diseases, such as high blood pressure (hypertension), elevated cholesterol (hyperlipidemia), and strategies for secondary prevention, in addition to respiratory ailments and diabetes. Established in 1946, Apontis Pharma AG maintains its corporate headquarters in Monheim am Rhein, Germany.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free